Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast Cancer

    NEXT STORY
    INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress
    PREV STORY
    Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Basilea provides corporate update

    author_avatar
    NASDAQ Market News

    Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry

    BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Biodesix® presented preliminary data evaluating a ...

    author_avatar
    NASDAQ Market News

    Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center to Develop Microbiome Metabolic Therapies (MMT™) in Immuno-oncology

    author_avatar
    NASDAQ Market News